ES2055772T3 - Uso del inositoltrisfosfato para la preparacion de un medicamento frente a alteraciones oseas. - Google Patents

Uso del inositoltrisfosfato para la preparacion de un medicamento frente a alteraciones oseas.

Info

Publication number
ES2055772T3
ES2055772T3 ES89117030T ES89117030T ES2055772T3 ES 2055772 T3 ES2055772 T3 ES 2055772T3 ES 89117030 T ES89117030 T ES 89117030T ES 89117030 T ES89117030 T ES 89117030T ES 2055772 T3 ES2055772 T3 ES 2055772T3
Authority
ES
Spain
Prior art keywords
inositoltrisphosphate
preparation
against bone
medicine against
bone alterations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89117030T
Other languages
English (en)
Inventor
Matti Siren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perstorp AB
Original Assignee
Perstorp AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perstorp AB filed Critical Perstorp AB
Application granted granted Critical
Publication of ES2055772T3 publication Critical patent/ES2055772T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION RELATA EL USO DE AL MENOS UN ISOMERO DE INOSITOLTRIFOSFATO (IP3) PARA PREPARAR MEDICAMENTOS QUE ALIVIEN, PREVENGAN O COMBATAN LOS DESORDENES OSEOS.
ES89117030T 1988-09-15 1989-09-14 Uso del inositoltrisfosfato para la preparacion de un medicamento frente a alteraciones oseas. Expired - Lifetime ES2055772T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8803248A SE464059C (sv) 1988-09-15 1988-09-15 Användning av inositoltrifosfat för framställning av läkemedel

Publications (1)

Publication Number Publication Date
ES2055772T3 true ES2055772T3 (es) 1994-09-01

Family

ID=20373330

Family Applications (5)

Application Number Title Priority Date Filing Date
ES89117028T Expired - Lifetime ES2045319T3 (es) 1988-09-15 1989-09-14 El uso del trifosfato de inosita en el tratamiento de da\os de tejido.
ES89117031T Expired - Lifetime ES2043998T3 (es) 1988-09-15 1989-09-14 El uso de inositoltrisfosfato para la preparacion de un medicamento contra los trastornos relacionados con trasplantes.
ES89117030T Expired - Lifetime ES2055772T3 (es) 1988-09-15 1989-09-14 Uso del inositoltrisfosfato para la preparacion de un medicamento frente a alteraciones oseas.
ES89117029T Expired - Lifetime ES2073419T3 (es) 1988-09-15 1989-09-14 Uso de inositatrifosfato en la preparacion de un medicamento contra la diabetes.
ES89117032T Expired - Lifetime ES2054965T3 (es) 1988-09-15 1989-09-14 El uso de un isomero de trifosfato de inositol para la preparacion de un medicamento contra niveles anormales de lipoproteinas en mamiferos.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES89117028T Expired - Lifetime ES2045319T3 (es) 1988-09-15 1989-09-14 El uso del trifosfato de inosita en el tratamiento de da\os de tejido.
ES89117031T Expired - Lifetime ES2043998T3 (es) 1988-09-15 1989-09-14 El uso de inositoltrisfosfato para la preparacion de un medicamento contra los trastornos relacionados con trasplantes.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES89117029T Expired - Lifetime ES2073419T3 (es) 1988-09-15 1989-09-14 Uso de inositatrifosfato en la preparacion de un medicamento contra la diabetes.
ES89117032T Expired - Lifetime ES2054965T3 (es) 1988-09-15 1989-09-14 El uso de un isomero de trifosfato de inositol para la preparacion de un medicamento contra niveles anormales de lipoproteinas en mamiferos.

Country Status (8)

Country Link
EP (5) EP0359260B1 (es)
JP (5) JP3058334B2 (es)
AT (5) ATE79542T1 (es)
DE (5) DE68904507T2 (es)
ES (5) ES2045319T3 (es)
GB (5) GB2223168B (es)
GR (4) GR3005448T3 (es)
SE (2) SE464059C (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
US5427956A (en) * 1989-03-08 1995-06-27 The University Of Virginia Patent Foundation Quantitative analysis for diabetic condition predictor
US5750348A (en) * 1989-03-08 1998-05-12 The University Of Virginia Patents Foundation Method for detecting insulin resistance
US5428066A (en) * 1989-03-08 1995-06-27 Larner; Joseph Method of reducing elevated blood sugar in humans
ES2146197T3 (es) * 1989-03-08 2000-08-01 Univ Virginia Suplemento dietetico para diabeticos resistentes a la insulina.
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
SE467340B (sv) * 1990-07-04 1992-07-06 Perstorp Ab Anvaendning av inositolmonofosfat foer framstaellning av ett laekemedel effektivt som en neuropeptid y-(npy-)antagonist
JP2750239B2 (ja) * 1991-08-14 1998-05-13 三共株式会社 アデノホスチンａまたはｂならびにその製法
SE503122C2 (sv) * 1993-11-22 1996-03-25 Perstorp Ab Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd
SE9600194D0 (sv) * 1996-01-19 1996-01-19 Perstorp Ab A new chemical compound
SE9601396D0 (sv) * 1996-04-12 1996-04-12 Dieter Haeussinger New therapeutic treatment 2
US5880098A (en) * 1996-04-12 1999-03-09 Pharmacia & Upjohn Aktiebolag Therapeutic treatment
SE9602463D0 (sv) * 1996-06-24 1996-06-24 Perstorp Ab The use of growth factor modulating compounds
US5998485A (en) * 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US5906979A (en) * 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
US6486127B1 (en) 2001-05-23 2002-11-26 Insmed, Incorporated Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof
KR100653557B1 (ko) * 2001-10-06 2006-12-05 아미코젠주식회사 카이로 이노시톨 또는 피니톨의 백내장 예방치료제로서의용도와 그 조성물
CN111246852A (zh) * 2017-10-26 2020-06-05 大塚制药株式会社 含有磷酸肌醇的组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
SE465305B (sv) * 1986-04-16 1991-08-26 Perstorp Ab Anvaendning av inositolfosfat foer framstaellning av ett laekemedel

Also Published As

Publication number Publication date
SE8803248L (sv) 1990-03-16
GB2223168B (en) 1992-08-12
JP3058334B2 (ja) 2000-07-04
DE68922165D1 (de) 1995-05-18
ATE84719T1 (de) 1993-02-15
GB8920805D0 (en) 1989-11-01
GB8920807D0 (en) 1989-11-01
EP0359258A3 (en) 1990-10-03
GR3015764T3 (en) 1995-07-31
EP0359256A2 (en) 1990-03-21
DE68904507T2 (de) 1993-06-09
ES2054965T3 (es) 1994-08-16
DE68922165T2 (de) 1995-09-14
GB2223404B (en) 1992-04-08
GB2223403B (en) 1992-02-26
EP0359257A2 (en) 1990-03-21
GB2223169A (en) 1990-04-04
EP0359256A3 (en) 1990-10-10
EP0359256B1 (en) 1993-01-20
GR3007686T3 (es) 1993-08-31
GB2223404A (en) 1990-04-11
DE68904507D1 (de) 1993-03-04
ATE104855T1 (de) 1994-05-15
SE464059C (sv) 1996-12-04
JPH02191218A (ja) 1990-07-27
GB8920811D0 (en) 1989-11-01
EP0359259A3 (en) 1990-10-03
ES2045319T3 (es) 1994-01-16
EP0359260A3 (en) 1990-10-03
JPH02191220A (ja) 1990-07-27
JP2859318B2 (ja) 1999-02-17
SE464059B (sv) 1991-03-04
GB8920804D0 (en) 1989-11-01
EP0359258A2 (en) 1990-03-21
EP0359257A3 (en) 1990-10-03
DE68914922D1 (de) 1994-06-01
ATE88347T1 (de) 1993-05-15
EP0359259A2 (en) 1990-03-21
GR3006825T3 (es) 1993-06-30
ATE120958T1 (de) 1995-04-15
JPH02191219A (ja) 1990-07-27
EP0359257B1 (en) 1995-04-12
DE68906106D1 (de) 1993-05-27
JPH02191217A (ja) 1990-07-27
GB2223167B (en) 1992-02-26
EP0359258B1 (en) 1994-04-27
EP0359259B1 (en) 1992-08-19
DE68902526D1 (de) 1992-09-24
JP2547257B2 (ja) 1996-10-23
DE68914922T2 (de) 1994-09-01
DE68902526T2 (de) 1993-03-11
ES2043998T3 (es) 1994-01-01
SE8803248D0 (sv) 1988-09-15
GB2223403A (en) 1990-04-11
SE9003395L (sv) 1992-04-25
JP2859319B2 (ja) 1999-02-17
EP0359260A2 (en) 1990-03-21
SE9003395D0 (sv) 1990-10-24
ES2073419T3 (es) 1995-08-16
DE68906106T2 (de) 1993-10-21
GB2223167A (en) 1990-04-04
GR3005448T3 (es) 1993-05-24
JPH02191221A (ja) 1990-07-27
ATE79542T1 (de) 1992-09-15
GB2223168A (en) 1990-04-04
EP0359260B1 (en) 1993-04-21
GB2223169B (en) 1992-04-08
GB8920806D0 (en) 1989-11-01

Similar Documents

Publication Publication Date Title
ES2055772T3 (es) Uso del inositoltrisfosfato para la preparacion de un medicamento frente a alteraciones oseas.
ES2064130T3 (es) Utilizacion de droloxifeno para el tratamiento de enfermedades de los huesos.
ES2093636T3 (es) Uso de un compuesto de 15-ceto-prostaglandina para la mejora de la funcion encefalica.
ES2024010B3 (es) Unidad de dosis farmaceutica.
EP0424156A3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
ES2161745T3 (es) Utilizacion de la trimetazidina para la obtencion de medicamentos destinados para el tratamiento de los trastornos relacionados con la nefrotoxicidad de la ciclosporina a.
ES1006927Y (es) Zapato para pacientes que han sufrido operacion quirurgica en la parte delantera del pie.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 359258

Country of ref document: ES